Oral Abstract Session - Session Chairs: Lugui Qiu/Ed Stadtmauer
To See the full abstracts:
OAB-001 - Overall Survival and Progression-free Survival by Treatment Duration With Daratumumab + Lenalidomide/ Dexamethasone in Transplant-ineligible Newly Diagnosed Multiple Myeloma: Phase 3 MAIA Study
Philippe Moreau, Thierry Facon, Shaji Kuma , et al.
Conclusions: After ~5 years of follow-up, D-Rd vs Rd showed a significant and clinically meaningful PFS and OS improvement in transplant-ineligible pts with NDMM. Additionally, D-Rd showed a greater PFS benefit vs Rd among pts treated for ≥18 months than among pts treated for shorter durations. Taken together with real-world data indicating that many transplant-ineligible pts do not receive a second line of therapy, the favorable benefit- risk profile observed in MAIA supports the frontline use of D-Rd in transplant-ineligible pts with NDMM.
Watch Philippe Moreau's comment on VJHEMONC - The Video Journal of Hematological Oncology:
OAB-002 - Daratumumab improves depth of response and progression free survival in transplant-ineligible, high-risk, newly diagnosed multiple myeloma (NDMM)
Andrzej Jakubowiak, Shaji Kumar, Rohan Medhekar, et al.
Conclusion: Addition of Dara to backbone regimens resulted in 41% reduction in risk of progression or death among ASCT-ineligible high-risk NDMM patients. Additionally, patients in the Dara cohort had a two-fold higher likelihood of achieving ≥CR and a five-fold higher likelihood of achieving MRD-negative CR relative to control. This study provides additional evidence that the use of Dara based first-line treatment benefits high-risk NDMM patients.
OAB-003 - CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM)
Rakesh Popat, William Wilson, Marquita Camilleri,et al.
Conclusions: K maintenance at 56mg/m2 weekly was deliverable and tolerable, with continued higher MRD neg rates at 6 months post-ASCT compared to post-Cons. However more ≥G3 AEs and discontinuations for AEs/ patient choice
OAB-004 - Carfilzomib-Based Induction/Consolidation With or Without Autologous Transplant and Lenalidomide (R) or Carfilzomib-Lenalidomide (KR) Maintenance: Efficacy in High-Risk Patients of the FORTE study
Roberto Mina, Elena Zamagni, Delia Rota- Scalabrini, et al.
Conclusion: KRd-ASCT and KR maintenance are highly effective in SR and also in HiR and DH pts, with impressive 4-year PFS from diagnosis (KRd-ASCT: HiR 62%, DH 55%) and 3-year PFS from maintenance (KR: HiR 69%, DH 67%), thus providing an effective option in HiR pts, who still represent an unmet medical need.
OAB-005 - Update of Safety and Efficacy of Isatuximab Short-Duration Fixed-Volume Infusion Plus Bortezomib, Lenalidomide, and Dexamethasone Combined Therapy for NDMM Ineligible/With No Immediate Intent for ASCT
Enrique Ocio, Aurore Perrot, Pierre Bories, et al.
Conclusions: These results confirm the feasibility, efficacy, and safety of the approved short-duration fixed-volume infusion method of Isa in combination with VRd in patients with NDMM ineligible/with no immediate intent for ASCT. Isa-VRd is under investigation in ongoing Phase 3 studies.
Oral Abstract Session - Session Chairs: Paola Neri/Dharminder Chauhan/Niklas Zojer
To See the full abstracts:
OAB-006 - A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma
Vincenza Solli, Andrea Poletti, Enrica Borsi, et al.
Conclusion: Our results showed that CT impact MM pts prognosis, independently from the genomic region affected and the pts’ genomic backgroung.
OAB-007 - Single-cell multiomic analysis identifies regulatory programs in relapsed/refractory multiple myeloma
Alexandra Poos, Moritz Przybilla, Nina Prokoph, et al.
Conclusions: In summary, our new approach to track individual tumor subclones over time indicates clonal adaptation or selection in virtually all RRMM patients and reveals new insights into regulatory mechanisms underlying treatment-resistance, opening potential avenues for new therapies.
OAB-008 - Identification of High-Risk Multiple Myeloma with a Plasma Cell Leukemia-Like Transcriptomic Profile
Davine Hofste op Bruinink, Rowan Kuiper, Mark van Duin, et al.
Conclusions: (1) pPCL cannot only be identified clinically, but also molecularly. (2) PCL-like status is a novel marker for HR disease in NDMM that identifies patients with a tumor transcriptome similar to pPCL and has independent prognostic value in the context of conventional HR markers. (3) PCL-like status could help detect NDMM patients with early stage or borderline pPCL.
OAB-009 - Genome-Wide CRISPR interference Screen Identifies RNA Regulator of Lipogenesis (RROL) as a Leading LncRNA Dependency in Multiple Myeloma
Eugenio Morelli, Mariateresa Fulciniti, Mehmet K Samur, et al.
Conclusion: In conclusion, we here report a unique regulatory function of a novel lncRNA supporting MM cell growth via its control of the lipogenic metabolic axis. The ongoing development of RROL inhibitors may allow clinical application of this unique targeted therapy in MM.
OAB-010 - Gain(1q) promotes mitochondrial oxidative phosphorylation and suppresses interferon response and tumor immunity in multiple myeloma and other human cancers
Rodger Tiedemann, Ali Mahdipour-Shirayeh, Natalie Erdmann, Ines Tagoug
Conclusion: Overall, from these multi-omic analyses we identify critical reprogramming events in MM and other human cancers that arise from +1q and that predict patient survival.
OAB-011 - Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single cell level
Yuting Yan, Xiaoqi Qin, Jiahui Liu, et al.
Conclusion: Survival after relapse were greater influenced by the presence of high-risk aberrations at relapse (hazard ratio =2.07) rather than present at diagnosis (hazard ratio=1.55). This study shows that QM-FISH is a valuable tool to elucidate the clonal architecture at single cell level. Clonal evolution pattern is of prognostic significance, highlighting the need for repeated cytogenetic evaluation in relapsed MM.